News

NEW YORK, NY, and TEL AVIV, ISRAEL, November 13, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)

NEW YORK, NY, November 08, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).

NEW YORK, NY, October 19, 2023 - Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche’s Evrysdi for $1.0 billion upfront.

NEW YORK, NY, October 11, 2023  - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. 

NEW YORK, NY, September 21, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee.

NEW YORK, NY, and COPENHAGEN, DENMARK, September 5, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue.

NEW YORK, NY, September 5, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 18 th Annual BioPharma Conference on Wednesday, September 6 at 11:20 a.m.

NEW YORK, NY, and SAINT PREX, SWITZERLAND, August 24, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s 

NEW YORK, NY, August 8, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).